AR058198A1 - Derivados de morfolina y composiciones farmaceuticas - Google Patents
Derivados de morfolina y composiciones farmaceuticasInfo
- Publication number
- AR058198A1 AR058198A1 ARP060105074A ARP060105074A AR058198A1 AR 058198 A1 AR058198 A1 AR 058198A1 AR P060105074 A ARP060105074 A AR P060105074A AR P060105074 A ARP060105074 A AR P060105074A AR 058198 A1 AR058198 A1 AR 058198A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- substituted
- atom
- substituents
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Uso del compuesto o sal como agente farmacéutico, y composiciones farmacéuticas que los comprenden Reivindicacion 1: Un compuesto caracterizado por la formula (1) o una sal aceptable para uso farmacologico del mismo, donde (a) R1, R2, R3 y R4 son iguales o diferentes y cada uno representa un átomo de H o un grupo alquilo C1-6; X1 representa un grupo alquileno C1-6, donde el grupo alquileno C1-6 puede estar sustituido con 1 a 3 grupos hidroxilo o grupos alquilo C1-6, donde los grupos alquilo C1-6 pueden estar sustituidos con 1 a 3 grupos hidroxilo, o un grupo cicloalquilo C3-13 formado por dos grupos alquilo C1-6 juntos unidos al mismo átomo de C del grupo alquileno C1-6; Xa representa un grupo metoxi o un átomo de F; Xb representa un átomo de O o un grupo metileno, siempre que Xb sea solamente un átomo de O cuando Xa es un grupo metoxi; y Ar1 representa un grupo arilo, grupo piridinilo, grupo ariloxi o grupo piridiniloxi que puede estar sustituido con 1 a 3 sustituyentes seleccionados del grupo de Sustituyentes A1; (b) Ar1-X1- representa un grupo cicloalquilo C3-8 condensado con un anillo bencénico, donde un grupo metileno en el grupo cicloalquilo C3-8 puede estar sustituido con un átomo de O, cicloalquilo C3-8 puede estar sustituido con 1 a 3 grupos hidroxilo y/o grupos alquilo C1-6 y el anillo bencénico puede estar sustituido con 1 a 3 sustituyentes seleccionados del Grupo de Sustituyentes A1; y R1, R2, R3, R4, Xa, y Xb son segun se definio en (a); (c) uno de R1 y R2 y un de R3 y R4 son iguales o diferentes y cada uno representa un átomo de H o un grupo alquilo C1-6; el otro de R1 y R2 y el otro de R3 y R4, junto con los átomos de C a los cuales están respectivamente unidos, forman un grupo cicloalquilo C3-8, donde el grupo cicloalquilo C3-8 puede estar sustituido con 1 a 3 sustituyentes seleccionados del Grupo de Sustituyentes A1; y X1, Xa, Xb y Ar1 son segun se definio en (a) o (b); (d) Ar1-X1- y R4 junto con el átomo de N al cual Ar1-X1-está unido y el átomo de C al cual R4 está unido, forman un grupo heterocíclico de 4 a 8 miembros que contiene N que puede estar sustituido con un grupo arilo o un grupo piridinilo, donde un grupo metileno en el grupo heterocíclico de 4 a 8 miembros que contiene N puede estar sustituido con un grupo metileno sustituido con 1 o 2 sustituyentes seleccionados del Grupo de Sustituyentes A1; un grupo vinileno que puede estar sustituido con 1 o 2 sustituyentes seleccionados del Grupo e Sustituyente A1, un átomo de O, o un grupo imino que puede estar sustituido con un sustituyente seleccionado del Grupo de Sustituyentes A1 y el grupo arilo o el grupo piridinilo puede estar sustituido con 1 a 3 sustituyentes seleccionados del Grupo de Sustituyentes A1; Xb representa un átomo de O; y R1, R2, R3 y Xa son segun se definio en (a) y (b); (e) R1 y R2, junto con el átomo de C al cual están unidos, forman un grupo cicloalquilo C3-8; y R3, R4, X1, Xa, Xb y Ar son segun se definio en (a) y (b); o (f) R3 y R4, junto con el átomo de C al cual están unidos, forman u grupo cicloalquilo C3-8; y R1, R2, X1, Xa, Xb y Ar1 son segun se definio en (a) y (b). (Grupo de Sustituyentes A1: (1) un átomo de halogeno; (2) un grupo hidroxilo; (3) un grupo ciano; (4) cicloalquilo C3-8; (5) cicloalcoxi C3-8; (6) alquilo C1-6, done el grupo alquilo C1-6 puede estar sustituido con 1 a 5 átomos de halogeno o uno a tres grupos alcoxi C1-6; (7) un grupo amino que puede estar sustituido con uno o dos grupos alquilo C1-6, donde los grupos alquilo C1-6 pueden estar sustituidos por 1 a 5 átomos de halogeno; (8) alcoxi C1-6, donde el grupo alcoxi C1-6 puede estar sustituido con 1 a 5 átomos de halogeno y (9) un grupo carbamoílo que puede estar sustituido con uno o dos grupos alquilo C1-6, donde los grupos alquilo C1-6 pueden estar sustituidos con 1 a 3 átomo de halogeno.).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005337952 | 2005-11-24 | ||
JP2006205591 | 2006-07-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR058198A1 true AR058198A1 (es) | 2008-01-23 |
Family
ID=38054331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060105074A AR058198A1 (es) | 2005-11-24 | 2006-11-20 | Derivados de morfolina y composiciones farmaceuticas |
Country Status (17)
Country | Link |
---|---|
US (1) | US7618960B2 (es) |
EP (1) | EP1953154A4 (es) |
JP (1) | JP5221144B2 (es) |
KR (1) | KR20080069221A (es) |
AR (1) | AR058198A1 (es) |
AU (1) | AU2006317457B2 (es) |
BR (1) | BRPI0618814A2 (es) |
CA (1) | CA2629745A1 (es) |
HK (1) | HK1122807A1 (es) |
MY (1) | MY144960A (es) |
NO (1) | NO20082604L (es) |
NZ (1) | NZ568050A (es) |
PE (1) | PE20070646A1 (es) |
RU (1) | RU2381225C1 (es) |
SA (1) | SA06270431B1 (es) |
TW (1) | TWI386207B (es) |
WO (1) | WO2007060810A1 (es) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100966749B1 (ko) | 2004-05-26 | 2010-06-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 신나미드 화합물 |
CN100577657C (zh) | 2004-10-26 | 2010-01-06 | 卫材R&D管理有限公司 | 肉桂酰胺化合物的无定形物 |
EP1953151A4 (en) * | 2005-11-18 | 2010-06-02 | Eisai R&D Man Co Ltd | SALTS FROM A CYNNAMIDE COMPOUND OR SOLVATE THEREOF |
AU2006316005A1 (en) * | 2005-11-18 | 2007-05-24 | Eisai R & D Management Co., Ltd. | Process for production of cinnamamide derivative |
MY144960A (en) | 2005-11-24 | 2011-11-30 | Eisai R&D Man Co Ltd | Morpholine type cinnamide compound |
TWI370130B (en) | 2005-11-24 | 2012-08-11 | Eisai R&D Man Co Ltd | Two cyclic cinnamide compound |
TWI378091B (en) | 2006-03-09 | 2012-12-01 | Eisai R&D Man Co Ltd | Multi-cyclic cinnamide derivatives |
CN101448793A (zh) * | 2006-05-19 | 2009-06-03 | 卫材R&D管理有限公司 | 脲型肉桂酰胺衍生物 |
AU2007252644A1 (en) * | 2006-05-19 | 2007-11-29 | Eisai R & D Management Co., Ltd. | Heterocyclic type cinnamide derivative |
SA07280403B1 (ar) | 2006-07-28 | 2010-12-01 | إيساي أر أند دي منجمنت كو. ليمتد | ملح رباعي لمركب سيناميد |
JP2010518080A (ja) * | 2007-02-08 | 2010-05-27 | メルク・シャープ・エンド・ドーム・コーポレイション | 治療薬 |
DE102007009810A1 (de) * | 2007-02-28 | 2008-09-04 | Man Roland Druckmaschinen Ag | Übertragungsform für einen Übertragungszylinder einer Druckmaschine |
TW200848054A (en) * | 2007-02-28 | 2008-12-16 | Eisai R&D Man Co Ltd | Two cyclic oxomorpholine derivatives |
WO2008138753A1 (en) * | 2007-05-11 | 2008-11-20 | F. Hoffmann-La Roche Ag | Hetarylanilines as modulators for amyloid beta |
WO2008140111A1 (ja) * | 2007-05-16 | 2008-11-20 | Eisai R & D Management Co., Ltd. | シンナミド誘導体のワンポット製造方法 |
CA2689948A1 (en) * | 2007-06-01 | 2008-12-18 | Schering Corporation | Gamma secretase modulators |
AU2008263206A1 (en) * | 2007-06-01 | 2008-12-18 | Schering Corporation | Gamma secretase modulators |
EP2166854A4 (en) * | 2007-06-13 | 2012-05-16 | Merck Sharp & Dohme | TRIAZOLE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND ASSOCIATED STATES |
EP2178857A1 (en) * | 2007-06-29 | 2010-04-28 | Schering Corporation | Gamma secretase modulators |
MX2010001506A (es) * | 2007-08-06 | 2010-03-10 | Schering Corp | Moduladores de gamma secretasa. |
CA2695864A1 (en) * | 2007-08-07 | 2009-02-12 | Schering Corporation | Gamma secretase modulators |
US7935815B2 (en) | 2007-08-31 | 2011-05-03 | Eisai R&D Management Co., Ltd. | Imidazoyl pyridine compounds and salts thereof |
AR068121A1 (es) | 2007-08-31 | 2009-11-04 | Eisai R&D Man Co Ltd | Compuestos multiciclicos para tratar enfermedades neurodegenerativas |
EP2200990A1 (en) | 2007-09-06 | 2010-06-30 | Schering Corporation | Gamma secretase modulators |
JP2010540524A (ja) * | 2007-09-28 | 2010-12-24 | シェーリング コーポレイション | ガンマセクレターゼモジュレーター |
US8487099B2 (en) | 2007-11-05 | 2013-07-16 | Merck Sharp & Dohme Corp. | Gamma secretase modulators |
US8426595B2 (en) * | 2007-12-11 | 2013-04-23 | Xianhai Huang | Gamma secretase modulators |
CA2708151A1 (en) * | 2007-12-11 | 2009-06-18 | Schering Corporation | Gamma secretase modulators |
CN101903372B (zh) * | 2007-12-21 | 2014-06-18 | 弗·哈夫曼-拉罗切有限公司 | 作为食欲肽受体拮抗剂的杂芳基衍生物 |
BRPI0906799A2 (pt) * | 2008-01-11 | 2015-07-14 | Hoffmann La Roche | Moduladores para amiloide beta |
WO2009096349A1 (ja) * | 2008-01-28 | 2009-08-06 | Eisai R & D Management Co., Ltd. | 結晶性のシンナミド化合物またはその塩 |
CA2713716A1 (en) | 2008-02-22 | 2009-08-27 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
EP2257542A1 (en) * | 2008-02-29 | 2010-12-08 | Schering Corporation | Gamma secretase modulators for the treatment of alzheimer ' s disease |
WO2010040661A1 (en) | 2008-10-09 | 2010-04-15 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
JP2012508180A (ja) * | 2008-11-06 | 2012-04-05 | シェーリング コーポレイション | γ−セクレターゼ調節剤 |
CA2742317A1 (en) * | 2008-11-06 | 2010-05-14 | Schering Corporation | Gamma secretase modulators |
EP2355817A1 (en) | 2008-11-10 | 2011-08-17 | F. Hoffmann-La Roche AG | Heterocyclic gamma secretase modulators |
JP5503663B2 (ja) * | 2008-11-13 | 2014-05-28 | メルク・シャープ・アンド・ドーム・コーポレーション | ガンマセクレターゼモジュレータ |
EP2365973A1 (en) * | 2008-11-13 | 2011-09-21 | Schering Corporation | Gamma secretase modulators |
EP2378879A4 (en) | 2008-12-16 | 2012-06-06 | Merck Sharp & Dohme | TRIAZONE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER |
TW201034666A (en) * | 2008-12-22 | 2010-10-01 | Schering Corp | Gamma secretase modulators |
TW201035103A (en) | 2008-12-22 | 2010-10-01 | Schering Corp | Gamma secretase modulators |
BRPI1007883A2 (pt) | 2009-02-26 | 2016-02-23 | Eisai R&D Man Co Ltd | sal, e, cristal. |
KR20110122746A (ko) | 2009-02-26 | 2011-11-10 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 질소를 함유하는 융합된 헤테로사이클릭 화합물 및 β 아밀로이드 생산 저해제로서의 용도 |
US20120245158A1 (en) | 2009-06-16 | 2012-09-27 | Xianhai Huang | Gamma secretase modulators |
US20120232108A1 (en) | 2009-06-16 | 2012-09-13 | Xianhai Huang | Gamma secretase modulators |
EP2443121A2 (en) | 2009-06-16 | 2012-04-25 | Schering Corporation | Gamma secretase modulators |
JP2012176901A (ja) * | 2009-09-25 | 2012-09-13 | Eisai R & D Management Co Ltd | 新規ベンゾニトリル化合物およびその製造方法 |
US20110190269A1 (en) * | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
US8486967B2 (en) | 2010-02-17 | 2013-07-16 | Hoffmann-La Roche Inc. | Heteroaryl substituted piperidines |
ES2602794T3 (es) | 2011-03-31 | 2017-02-22 | Pfizer Inc | Piridinonas bicíclicas novedosas |
CN102675240B (zh) * | 2012-04-13 | 2015-01-14 | 浙江海正药业股份有限公司 | 4-取代基-2-羟基吗啉-3-酮及其制备方法 |
UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
EA033423B1 (ru) | 2015-02-03 | 2019-10-31 | Pfizer | Циклопропанбензофуранилпиридопиразиндионы |
CA3016253C (en) * | 2016-02-29 | 2020-12-29 | Bio-Pharm Solutions Co., Ltd. | Sulfamate derivative compounds, processes for preparing them and their uses |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3689506D1 (de) | 1985-10-09 | 1994-02-17 | Shell Int Research | Neue Acrylsäureamide. |
DE3541716A1 (de) | 1985-11-26 | 1987-05-27 | Celamerck Gmbh & Co Kg | Neue acrylsaeureamide |
JPH03206042A (ja) | 1990-01-06 | 1991-09-09 | Takeda Chem Ind Ltd | 降圧剤 |
ATE153655T1 (de) * | 1990-02-08 | 1997-06-15 | Eisai Co Ltd | Benzensulfonamidderivat |
AU680870B2 (en) * | 1993-04-28 | 1997-08-14 | Astellas Pharma Inc. | New heterocyclic compounds |
JPH10510512A (ja) | 1994-10-04 | 1998-10-13 | 藤沢薬品工業株式会社 | 尿素誘導体とacat阻害剤としての用途 |
JPH08283219A (ja) | 1995-04-07 | 1996-10-29 | Eisai Co Ltd | アラルキルアミノアルキルアミド誘導体 |
JP3418405B2 (ja) | 1996-05-10 | 2003-06-23 | アイコス コーポレイション | カルボリン誘導体 |
JP2000515153A (ja) | 1996-07-22 | 2000-11-14 | モンサント カンパニー | チオールスルホンアミド メタロプロテアーゼインヒビター |
WO1998024785A1 (en) | 1996-12-02 | 1998-06-11 | Fujisawa Pharmaceutical Co., Ltd. | Indole-urea derivatives with 5-ht antagonist properties |
CA2281875A1 (en) | 1997-03-31 | 1998-10-08 | Takeda Chemical Industries, Ltd. | Azole compounds, their production and their use |
JP3108997B2 (ja) | 1997-03-31 | 2000-11-13 | 武田薬品工業株式会社 | アゾール化合物、その製造法および用途 |
WO1999033846A2 (en) | 1997-12-31 | 1999-07-08 | The University Of Kansas | Water soluble prodrugs of secondary and tertiary amine containing drugs and methods of making thereof |
GB9816984D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Plc | Novel compounds |
US6235728B1 (en) * | 1999-02-19 | 2001-05-22 | Bristol-Myers Squibb Company | Water-soluble prodrugs of azole compounds |
KR20020006626A (ko) | 1999-02-26 | 2002-01-23 | 폴락 돈나 엘. | 신규한 술폰아미드 화합물 및 그의 용도 |
WO2000051981A1 (en) * | 1999-03-04 | 2000-09-08 | Nortran Pharmaceuticals Inc. | Aminocycloalkyl cinnamide compounds for arrhythmia and as analgesics and anesthetics |
US20040087798A1 (en) * | 2000-03-14 | 2004-05-06 | Akira Yamada | Novel amide compounds |
US20010051642A1 (en) * | 2000-04-17 | 2001-12-13 | Kyunghye Ahn | Method for treating Alzheimer's disease |
WO2001081312A2 (en) | 2000-04-24 | 2001-11-01 | Merck Frosst Canada & Co. | Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore |
EP1349839B8 (en) * | 2000-12-04 | 2005-06-22 | F. Hoffmann-La Roche Ag | Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists |
GB0108770D0 (en) | 2001-04-06 | 2001-05-30 | Eisai London Res Lab Ltd | Inhibitors |
JPWO2003043988A1 (ja) * | 2001-11-22 | 2005-03-10 | 小野薬品工業株式会社 | ピペリジン−2−オン誘導体化合物およびその化合物を有効成分として含有する薬剤 |
PL373484A1 (en) | 2001-12-10 | 2005-09-05 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
ATE430727T1 (de) | 2001-12-20 | 2009-05-15 | Bristol Myers Squibb Co | Alpha-(n-sulfonamid)acetamidderivate als beta- amyloidinhibitoren |
JP2003206280A (ja) | 2001-12-28 | 2003-07-22 | Takeda Chem Ind Ltd | ビアリール化合物およびその用途 |
GB0207436D0 (en) | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
ES2355472T3 (es) * | 2002-05-22 | 2011-03-28 | Amgen Inc. | Derivados de aminopirimidina para su uso como ligandos del receptor vaniloide para el tratamiento del dolor. |
SI1511710T1 (sl) | 2002-05-31 | 2014-04-30 | Proteotech, Inc. | Spojine, sestavki in postopki za zdravljenje amiloidnih bolezni in sinukleinopatij, kot je Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsova bolezen |
MXPA05000053A (es) | 2002-07-12 | 2005-04-08 | Aventis Pharma Gmbh | Benzoilureas heterociclicamente sustituidas, metodo para su produccion y su uso como medicamentos. |
US6900354B2 (en) * | 2002-07-15 | 2005-05-31 | Hoffman-La Roche Inc. | 3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives |
WO2004071447A2 (en) * | 2003-02-12 | 2004-08-26 | Transtech Pharma Inc. | Substituted azole derivatives as therapeutic agents |
US7244739B2 (en) | 2003-05-14 | 2007-07-17 | Torreypines Therapeutics, Inc. | Compounds and uses thereof in modulating amyloid beta |
US8362017B2 (en) * | 2003-08-29 | 2013-01-29 | Exelixis, Inc. | C-kit modulators and methods of use |
US20050187277A1 (en) * | 2004-02-12 | 2005-08-25 | Mjalli Adnan M. | Substituted azole derivatives, compositions, and methods of use |
KR100966749B1 (ko) * | 2004-05-26 | 2010-06-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 신나미드 화합물 |
CN100577657C (zh) | 2004-10-26 | 2010-01-06 | 卫材R&D管理有限公司 | 肉桂酰胺化合物的无定形物 |
US20060241038A1 (en) | 2005-04-20 | 2006-10-26 | Eisai Co., Ltd. | Therapeutic agent for Abeta related disorders |
WO2007034282A2 (en) | 2005-09-19 | 2007-03-29 | Pfizer Products Inc. | Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists |
EP1953151A4 (en) * | 2005-11-18 | 2010-06-02 | Eisai R&D Man Co Ltd | SALTS FROM A CYNNAMIDE COMPOUND OR SOLVATE THEREOF |
AU2006316005A1 (en) * | 2005-11-18 | 2007-05-24 | Eisai R & D Management Co., Ltd. | Process for production of cinnamamide derivative |
TWI370130B (en) | 2005-11-24 | 2012-08-11 | Eisai R&D Man Co Ltd | Two cyclic cinnamide compound |
MY144960A (en) | 2005-11-24 | 2011-11-30 | Eisai R&D Man Co Ltd | Morpholine type cinnamide compound |
US20070117839A1 (en) * | 2005-11-24 | 2007-05-24 | Eisai R&D Management Co., Ltd. | Two cyclic cinnamide compound |
JP4246779B2 (ja) | 2005-11-25 | 2009-04-02 | 旭化成ケミカルズ株式会社 | ジアルキルカーボネートとジオール類を工業的に製造する方法 |
TWI378091B (en) * | 2006-03-09 | 2012-12-01 | Eisai R&D Man Co Ltd | Multi-cyclic cinnamide derivatives |
GEP20115139B (en) | 2006-03-09 | 2011-01-10 | Eisai R&D Man Co Ltd | Polycyclic cinnamide derivative |
SA07280403B1 (ar) * | 2006-07-28 | 2010-12-01 | إيساي أر أند دي منجمنت كو. ليمتد | ملح رباعي لمركب سيناميد |
JP2010518080A (ja) | 2007-02-08 | 2010-05-27 | メルク・シャープ・エンド・ドーム・コーポレイション | 治療薬 |
KR20100017573A (ko) | 2007-05-07 | 2010-02-16 | 쉐링 코포레이션 | 감마 세크레타제 조정인자 |
WO2008138753A1 (en) * | 2007-05-11 | 2008-11-20 | F. Hoffmann-La Roche Ag | Hetarylanilines as modulators for amyloid beta |
EP2166854A4 (en) | 2007-06-13 | 2012-05-16 | Merck Sharp & Dohme | TRIAZOLE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND ASSOCIATED STATES |
MX2010001506A (es) | 2007-08-06 | 2010-03-10 | Schering Corp | Moduladores de gamma secretasa. |
-
2006
- 2006-10-27 MY MYPI20081694A patent/MY144960A/en unknown
- 2006-10-27 NZ NZ568050A patent/NZ568050A/en not_active IP Right Cessation
- 2006-10-27 RU RU2008125426/04A patent/RU2381225C1/ru not_active IP Right Cessation
- 2006-10-27 BR BRPI0618814-1A patent/BRPI0618814A2/pt not_active IP Right Cessation
- 2006-10-27 EP EP06832397.1A patent/EP1953154A4/en not_active Withdrawn
- 2006-10-27 CA CA002629745A patent/CA2629745A1/en not_active Abandoned
- 2006-10-27 TW TW095139716A patent/TWI386207B/zh not_active IP Right Cessation
- 2006-10-27 JP JP2007546382A patent/JP5221144B2/ja not_active Expired - Fee Related
- 2006-10-27 AU AU2006317457A patent/AU2006317457B2/en not_active Ceased
- 2006-10-27 KR KR1020087013158A patent/KR20080069221A/ko active IP Right Grant
- 2006-10-27 WO PCT/JP2006/321473 patent/WO2007060810A1/ja active Application Filing
- 2006-11-08 US US11/594,130 patent/US7618960B2/en not_active Expired - Fee Related
- 2006-11-20 AR ARP060105074A patent/AR058198A1/es not_active Application Discontinuation
- 2006-11-21 PE PE2006001480A patent/PE20070646A1/es not_active Application Discontinuation
- 2006-11-22 SA SA06270431A patent/SA06270431B1/ar unknown
-
2008
- 2008-06-11 NO NO20082604A patent/NO20082604L/no not_active Application Discontinuation
- 2008-12-29 HK HK08114016.3A patent/HK1122807A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR20080069221A (ko) | 2008-07-25 |
SA06270431B1 (ar) | 2010-07-03 |
AU2006317457A1 (en) | 2007-05-31 |
WO2007060810A1 (ja) | 2007-05-31 |
BRPI0618814A2 (pt) | 2014-04-29 |
JP5221144B2 (ja) | 2013-06-26 |
US7618960B2 (en) | 2009-11-17 |
TWI386207B (zh) | 2013-02-21 |
CA2629745A1 (en) | 2007-05-31 |
RU2381225C1 (ru) | 2010-02-10 |
PE20070646A1 (es) | 2007-07-30 |
MY144960A (en) | 2011-11-30 |
NO20082604L (no) | 2008-08-21 |
NZ568050A (en) | 2010-09-30 |
US20070117798A1 (en) | 2007-05-24 |
AU2006317457B2 (en) | 2011-09-08 |
TW200730514A (en) | 2007-08-16 |
EP1953154A4 (en) | 2013-11-20 |
JPWO2007060810A1 (ja) | 2009-05-07 |
HK1122807A1 (en) | 2009-05-29 |
EP1953154A1 (en) | 2008-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR058198A1 (es) | Derivados de morfolina y composiciones farmaceuticas | |
AR062095A1 (es) | Profarmaco de compuesto cinamida | |
AR070992A1 (es) | Derivados de 2-aril-6-fenil-inidazo[1,2a]piridinas, su preparacion, composiciones farmaceuticas y su uso en enfermedades que implican los receptores nucleares nurr-1 | |
AR057915A1 (es) | Compuesto con estructura de cinamida de dos ciclos con actividad inhibitoria de la produccion de abeta40 y abeta42, un agente farmaceutico que lo comprende y el uso de este en el tratamiento de enfermedades mentales y neurodegenerativas. | |
AR080596A1 (es) | Compuestos alquilamido y composiciones farmaceuticas | |
ES2530943T3 (es) | Derivados de la cromenona con actividad antitumoral | |
AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
CO6160237A2 (es) | Pirazinonas y pirazinoles sustituidos y composiciones que los comprenden | |
CO6140033A2 (es) | Amino-imidazoles y su uso como medicamento para tratar discapacidad coognotiva enfermedad de alzheimer neurodegeneracion y demencia | |
CO5580815A2 (es) | Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen | |
AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
AR073369A1 (es) | Derivados de 2-carboxamida-cicloamino-urea como inhibidores de pi-3 | |
AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
AR052419A1 (es) | Derivados de bencimidazolil n-sustituidos,inhibidores del protooncogen c-kit | |
AR054365A1 (es) | Derivados de heteroaril benzamidas, composiciones farmaceuticas que los contienen, usos en enfermedades mediadas por glucoquinasasy metodo de preparacion de los mismos. | |
AR048974A1 (es) | Derivados sustituidos del dioxido de oxazol-benzoisotiazol y composiciones farmaceuticas. | |
NI200900037A (es) | Derivados de 2-aril-6-fenil-imidazo[1,2-alfa] piridinas, su preparación y su aplicación en terapéutica. | |
AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
AR062110A1 (es) | Derivado de anillo fusionado de espiroquetas y su uso como farmaco antidiabetico | |
AR056645A1 (es) | Compuestos de urea sustituida inhibidores de enzimas chk1 . | |
UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
AR056025A1 (es) | Compuestos de imidazol sustituidos como inhibidores de ksp | |
AR101704A1 (es) | Compuestos heterocíclicos fusionados | |
AR087274A1 (es) | Derivados de amidas heterociclicas como antagonistas de receptores p2x7 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |